Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

ImmunGene Announces Multi-Target R & D Collaboration With Cephalon Australia for Interferon Payload Technology

January 5, 2011 By Bio-Medicine.Org

THOUSAND OAKS, Calif., Jan. 5, 2011 /PRNewswire/ — ImmunGene,
Inc., a privately held drug development company focused on targeted
antibody therapeutics, announced today it has entered into a
collaboration in which Cephalon Australia (a wholly owned
subsidiary of Cephalon, Inc.) will apply ImmunGene’s interferon
payload technology to up to six of its new drug targets for
cancers.

Under terms of the collaboration, Cephalon Australia will pay
undisclosed fees including an up-front payment to ImmunGene for a
four-year option to leverage ImmunGene’s novel drug development
technology in preclinical research on up to six of Cephalon
Australia’s drug candidates. Cephalon has the option to pay
ImmunGene license fees for exclusivity on each of these candidates
that it decides to move into clinical trials.

Cephalon Australia is responsible for research, clinical
development, manufacturing and commercialization of products that
result from the ImmunGene collaboration.  ImmunGene is
eligible to receive considerable payments for research, clinical
and regulatory milestones for each drug candidate in the
collaboration that is commercialized, in addition to royalties on
worldwide net sales of any resulting products.

Dr. Sanjay Khare, CEO of ImmunGene, said, “This collaboration is
a validation of ImmunGene’s novel antibody function enhancement
technology that adds the power of cytokines to antibodies while
reducing the systemic toxicity of the cytokines.”  Dr. Raj
Sachdev, ImmunGene’s Chief Operating Officer, added, “We are
pleased to have Cephalon Australia as a partner with its strong
commitment to advancing this new class of protein
therapeutics.”

ImmunGene is leveraging promising science to tap the power of
the immune system to develop therapeutic antibodies with increased
efficacy and superior safety compared to existing therapies.

ImmunGene’s breakthrough technology platform, available for
non-exclusive licensing, offers phar

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 27, 2022
Quick message - No DTW podcast, but plenty else to listen to over this weekend and next week.
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech